Journal
BIOMOLECULES
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/biom11081189
Keywords
ME/CFS; human activin B; visual analogue scale
Categories
Funding
- Latvian Science Council's Fundamental and Applied Research project [LZP-2019/1-0380]
Ask authors/readers for more resources
The study found no significant difference in activin B levels between ME/CFS patients and healthy controls, with no gender or age-related differences observed either. Activin B levels tended to decrease with increasing visual analogue scale score, but the results do not support its clinical utility as a biomarker for ME/CFS at this time.
Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a disabling and complex disease for which diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls. Analyses of human activin B level in plasma samples were performed using a validated human activin B ELISA assay. The results of the study show that activin B levels did not differ statistically significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age-related differences in activin B levels were observed in the ME/CFS group and healthy controls. The level of activin B tended to decrease with increasing visual analogue scale score (r = -0.2004; p = 0.5085) nevertheless the results obtained so far does not support the clinical utility of activin B as a biomarker for ME/CFS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available